The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, welcomes the decision by the U.S. Food and Drug Administration (FDA) approving Genentech’s Tecentriq ® (atezolizumab) plus Cotellic ® (cobimetinib) and Zelboraf ® (vemurafenib) for the treatment of BRAF V600 mutation-positive advanced melanoma patients.
Publications
Prognosis of patients with stage III melanoma according to American Joint Committee on Cancer Version 8: A reassessment on the basis of 3 independent stage III melanoma cohorts
Given that three new therapies were approved recently for the adjuvant treatment of stage III melanoma, substantially decreasing the risk of tumor recurrences, researchers assessed three independent data sets to clarify the survival probabilities of individuals with stage III melanoma.
Usefulness of neuron-specific enolase as a serum marker of metastatic melanoma
Given that the likely usefulness of serum neuron?specific enolase (sNSE) as a marker for melanoma has been suggested in some previous reports, but there is controversy regrading its usefulness, so, researchers retrospectively assessed sNSE as well as serum lactate dehydrogenase (sLDH) concentrations at the initial diagnosis and during therapy in a total of 33 melanoma patients of various stages.
Prognostic significance of acral lentiginous histologic type in T1 melanoma
Researchers investigated if the poor result of acral lentiginous melanoma (ALM) is because of its inherent disease features or advanced stage at initial diagnosis.